MedTrace Logo

Examination of the Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections

NCT01507974 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2020-05-19

No results posted yet for this study

Summary

Urinary tract infection is the most common bacterial infection during pregnancy. Asymptomatic bacteriuria is the most common infection, in up to 8% of the population. Symptomatic infection may cause cystitis or cause pyelonephritis.

Among pregnant women with recurrent bacteriuria, preventive antibiotic treatment has been found to be efficacious in reducing the bacteriuria rate and the complications.

the changes of the urinary tract which appear during pregnancy usually resolve up to 3 months post-partum.

The purpose of this study is to examine the efficacy of preventive antibiotic treatment during the puerperium.

Conditions

  • Pregnancy Complications

Interventions

DRUG

Preventive antibiotic treatment- NITROFURANTOIN

P.O NITROFURANTOIN 100 mg per day for 6 weeks

DRUG

Preventive antibiotic treatment- CEPHALEXIN

P.O CEPHALEXIN 500 MG PER DAY FOR 6 WEEKS

DRUG

PREVENTIVE TREATMENT- AMOXICILLIN

P.O AMOXICILLIN 250 MG PER DAY FOR 6 WEEKS

DRUG

PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM

P.O AMOXICILLIN AND CLAVULANATE POTASSIUM, 875 MG PER DAY FOR 6 WEEKS

DRUG

PREVENTIVE TREATMENT- CEFUROXIME

P.O CEFUROXIME 250 MG PER DAY FOR 6 WEEKS

DRUG

PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM

P.O SULFAMETHOXAZOLE AND TRIMETHOPRIM 1 TAB PER DAY FOR 6 WEEKS

Sponsors & Collaborators

  • HaEmek Medical Center, Israel

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-16
Primary Completion
2014-07-01
Completion
2015-01-01

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01507974 on ClinicalTrials.gov